Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News aTyr Pharma Inc ATYR

Healthcare Biotechnology
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ATYR)

aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from "LIFE" to "ATYR"

GlobeNewswire June 3, 2024

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 24, 2024

aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference

GlobeNewswire May 15, 2024

aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT(TM) Study in Pulmonary Sarcoidosis

GlobeNewswire May 14, 2024

aTyr Pharma to Present at Upcoming Investor Conferences

GlobeNewswire May 6, 2024

aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update

GlobeNewswire May 2, 2024

aTyr Pharma to Participate in April Investor Conferences

GlobeNewswire April 1, 2024

aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

GlobeNewswire March 14, 2024

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results

GlobeNewswire February 28, 2024
View More News ››

Opinion & Analysis (NDAQ:ATYR)

Kyorin's $175M Partnership Offers Good Life for aTyr Pharma in Japan

Streetwise Reports January 7, 2020

Expedition Mining (V.EXU) poised to target $28 billion endoscopy equipment market

Richard (Rick) Mills July 27, 2015
View More Opinion ››

Bullboard Posts (NDAQ:ATYR)

LIFE - Monday Rundown, Tuesday Expectations

<< View Post To Watch Video >>
HDavis - September 13, 2021

Life Technologies Announces Fourth Quarter and Fis

Life Technologies Announces Fourth Quarter and Fiscal 2012 Results Fourth quarter revenue increased 3% to $999 million, or 4.5...
bc4u - February 4, 2013

Where are you Posters?...

I have been patiently waiting to see some other investors post something of value on this board...obviously to no avail. So I guess that...
fedora - May 9, 2001

There's something here

For months you guys have been ignoring this stock. I t has a captive market, i.e. the invalid and the aging and it's margins are...
fedora - April 17, 2001
View more Bullboard ››

K9 Gold Corp

K9 Gold Corp

K9 Gold Corp. is engaged in the business of identification, acquisition and exploration of mineral interests. The Company’s ...
View More »